4SC AG
Biopharmaceutical company with no products under development or operational business.
VSC | F
Overview
Corporate Details
- ISIN(s):
- DE000A3E5C40
- LEI:
- 391200QOKN7LGVP0RQ86
- Country:
- Germany
- Address:
- Fraunhoferstr. 22, 82152 Planegg
- Website:
- https://www.4sc.com/
- Sector:
- Manufacturing
Description
4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-12-19 00:00 |
Datum:19.12.2019
|
German | HTML • 11.1 KB | ||
| 2019-12-13 07:30 |
4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + av…
|
English | HTML • 12.7 KB | ||
| 2019-11-20 14:51 | English | HTML • 19.0 KB | |||
| 2019-11-19 13:32 | English | HTML • 19.0 KB | |||
| 2019-11-14 16:15 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | HTML • 4.3 KB | ||
| 2019-11-12 14:07 |
4SC AG secures circa EUR 22.4 million from a capital increase
|
English | HTML • 10.2 KB | ||
| 2019-10-30 00:00 |
Q3 statement / Q3 financial report 2019
|
English | PDF • 237.6 KB | ||
| 2019-10-21 07:30 |
4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carci…
|
English | HTML • 11.0 KB | ||
| 2019-10-17 07:30 |
4SC provides Q3 business update and outlook
|
English | HTML • 13.0 KB | ||
| 2019-10-16 07:30 |
4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Doma…
|
English | HTML • 15.4 KB | ||
| 2019-10-10 07:30 |
4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Annou…
|
English | HTML • 9.4 KB | ||
| 2019-10-07 16:46 |
4SC AG resolves to issue new shares; Santo and ATS undertake to subscribe / buy…
|
English | HTML • 14.5 KB | ||
| 2019-09-30 12:00 |
4SC AG: First domatinostat combination data from Phase Ib/II SENSITIZE study pr…
|
English | HTML • 14.5 KB | ||
| 2019-09-27 07:30 |
4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF …
|
English | HTML • 14.0 KB | ||
| 2019-09-23 00:05 |
4SC AG: Poster presentations at ESMO Congress 2019
|
English | HTML • 16.5 KB |
Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for 4SC AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for 4SC AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
